Key result
Exposure of HMEC-1 cells to cyclosporine A and combined tacrolimus-sirolimus significantly increased ICAM-1 expression (157.5 and 153.4 vs 105.7 MGV, P<0.05), which was attenuated by defibrotide.
Why the study?
Does defibrotide protect microvascular endothelial cells from the deleterious effects of immunosuppressive agents?
Does defibrotide protect microvascular endothelial cells from the deleterious effects of immunosuppressive agents?
Absolute Event Rate: 157.5% vs 105.7%
p-value: p=< .05
Defibrotide exerts protective anti-inflammatory and antithrombotic effects on endothelial cells exposed to immunosuppressive agents like cyclosporine and tacrolimus+sirolimus.
Defibrotide may attenuate endothelial activation by calcineurin inhibitors in vitro; hypothesis-generating and requires clinical validation before transplant use.
Endothelial dysfunction seems to be a key factor in the development of several complications observed early after hematopoietic stem cell transplantation (HSCT). The conditioning regimen and many other factors associated with the procedure are responsible for this endothelial damage. The effects of immunosuppressive agents on endothelial function have not been explored in detail. We evaluated the effects of 3 drugs commonly used in HSCT: 2 calcineurin inhibitors, cyclosporine A (CSA) and tacrolimus (TAC), and an inhibitor of mTOR, sirolimus (SIR). We also evaluated the effect of the combination of TAC and SIR (TAC+SIR), which is used increasingly in clinical practice. Microvascular endothelial cells (HMEC-1) were exposed to these drugs to evaluate changes in (1) intercellular adhesion molecule (ICAM)-1 expression on the cell surface, assessed by immunofluorescence labeling and expressed as the mean gray value (MGV); (2) reactivity of the extracellular matrix (ECM) toward platelets, upon exposure of the ECM to circulating blood; and (3) whole-blood clot formation, assessed by thromboelastometry. Studies were conducted in the absence and presence of defibrotide (DF) to assess its possible protective effect. The exposure of HMEC-1 to CSA and TAC+SIR significantly increased the expression of ICAM-1 (157.5 ± 11.6 and 153.4 ± 9.5 MGV, respectively, versus 105.7 ± 6.5 MGV in controls [both P < .05]). TAC applied alone increased ICAM-1 slightly (120.3 ± 8.2 MGV), and SIR had no effect (108.9 ± 7.4 MGV). ECM reactivity increased significantly only in response to CSA (surface covered by platelets of 41.2% ± 5.4% versus 30.1% ± 2.0%, P < .05). DF attenuated all these changes. No significant changes in the viscoelastic properties of clot formation were observed in any condition with blood samples incubated in vitro. In conclusion, CSA and TAC+SIR had a proinflammatory effect, but only CSA exhibited an additional prothrombotic effect. Interestingly, DF exerted clear protective anti-inflammatory and antithrombotic effects on the endothelium.
No takes yet. Share an insight, caveat, or question.
Carmona et al. (2013) studied Endothelial dysfunction related to hematopoietic stem cell transplantation. Cyclosporine A, tacrolimus, sirolimus, and combined tacrolimus-sirolimus, with or without defibrotide vs. Controls (unexposed cells) was evaluated on Intercellular adhesion molecule (ICAM)-1 expression on the cell surface (MGV) (p=< .05). Exposure of HMEC-1 cells to cyclosporine A and combined tacrolimus-sirolimus significantly increased ICAM-1 expression (157.5 and 153.4 vs 105.7 MGV, P<0.05), which was attenuated by defibrotide.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: